Seoul: Celltrion Inc., a prominent South Korean biopharmaceutical company, announced a remarkable increase in its 2025 net profit, reaching 1.03 trillion won (US$708.5 million), marking a 146.2 percent rise from the previous year.
According to Yonhap News Agency, the company revealed in a regulatory filing that its operating profit for the year amounted to 1.16 trillion won, a significant increase from 492 billion won recorded in the previous year. In addition, Celltrion's annual sales experienced a 17 percent growth, totaling 4.16 trillion won.